Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Isotopia","sponsor":"Seibersdorf Labor GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Isotopia","sponsor":"CPDC Centre for Probe Development and Commercialization","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Isotopia","sponsor":"Clovis Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Isotopia","sponsor":"Philochem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Philochem AG, Seibersdorf Labor GmbH and Isotopia Announce Supply, Development, And Manufacturing Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Isotopia

    Menu

    Isotopia

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Isotopia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Philochem AG, Seibersdorf Labor GmbH and Isotopia Announce Supply, Development, And Manufacturing Agreements

              Details:

              177Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other 177Lu-FAP-ligands.

              Lead Product(s): 177Lu-OncoFAP-23

              Therapeutic Area: Oncology Product Name: 177Lu-OncoFAP-23

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Philochem

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration December 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Isotopia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

              Details:

              177Lu-FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach medical radioisotopes, such as lutetium-177 for therapeutic use, or gallium-68 for imaging use.

              Lead Product(s): 177Lu-FAP-2286

              Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286

              Highest Development Status: Phase I/ Phase II Product Type: Peptide

              Recipient: Clovis Oncology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Isotopia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

              Details:

              177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.

              Lead Product(s): No-Carrier-Added Lutetium-177

              Therapeutic Area: Oncology Product Name: n.c.a 177 Lu

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: CPDC Centre for Probe Development and Commercialization

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Isotopia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a.

              Details:

              Seibersdorf Labor, a GMP Contract manufacturing of radiopharmaceuticals, a global leader in the development, production, and commercialization of radiopharmaceuticals, will produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for distribution in Europe.

              Lead Product(s): No-carrier-added Lutetium-177

              Therapeutic Area: Oncology Product Name: 177Lu n.c.a

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Seibersdorf Labor GmbH

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY